See every side of every news story
Published loading...Updated

Apotex Receives Health Canada Approval for Aflivu™, a Biosimilar to Eylea®, Available in Pre-Filled Syringe and Vial Formats

Summary by TBNweekly
TORONTO, July 2, 2025 /PRNewswire/ - Apotex Inc. ("Apotex" or the "Company"), the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration,…

16 Articles

The Globe & MailThe Globe & Mail
+12 Reposted by 12 other sources
Center

Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats

Newswire.ca Press Release.

·Canada
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 71% of the sources are Center
71% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Globe & Mail broke the news in Canada on Wednesday, July 2, 2025.
Sources are mostly out of (0)